目的 探討奧沙西泮聯(lián)合阿米替林治療抑郁癥的臨床療效。方法 選取2020年12月-2021年12月蕪湖市第四人民醫(yī)院精神科診療的100例伴軀體癥狀抑郁癥患者,按照隨機(jī)數(shù)字表法分為對(duì)照組和治療組,每組各50例。對(duì)照組患者口服鹽酸阿米替林片, 25 mg/次, 3次/d。治療組在對(duì)照組的基礎(chǔ)上口服奧沙西泮片, 30 mg/次, 3次/d。兩組患者持續(xù)治療8周。觀察兩組的臨床療效和癥狀改善時(shí)間。比較兩組治療前后漢密爾頓抑郁量表(HAMD)評(píng)分、癥狀自評(píng)量表(SCL-90)評(píng)分及血清白細(xì)胞介素6(IL-6)、白細(xì)胞介素2(IL-2)、腫瘤壞死因子(TNF-α)、白細(xì)胞介素1β(IL-1β)水平的變化情況。結(jié)果 治療后,治療組總有效率是98.0%,顯著高于對(duì)照組的80.0%(P<0.05)。經(jīng)治療,治療組出現(xiàn)入睡困難、食欲下降、疲乏無力、情緒煩躁等癥狀改善時(shí)間均顯著短于對(duì)照組(P<0.05)。治療后,兩組HAMD評(píng)分、SCL-90評(píng)分均較治療前顯著降低(P<0.05);治療后,治療組HAMD評(píng)分、SCL-90評(píng)分均低于對(duì)照組(P<0.05)。治療后,兩組血清IL-6、IL-2、TNF-α、IL-1β水平均較治療前顯著降低(P<0.05);治療組血清學(xué)指標(biāo)水平低于對(duì)照組(P<0.05)。結(jié)論 奧沙西泮聯(lián)合阿米替林治療伴軀體癥狀抑郁癥效果確切,可明顯改善癥狀,降低炎性細(xì)胞因子,值得臨床推廣。

Objective To investigate the efficacy of oxazepam combined with amitriptyline in treatment of depression.Methods A total of 100 cases of depression with somatic symptoms treated in the Department of Psychiatry of The Fourth People’s Hospital of Wuhu from December 2020 to December 2021 were selected and divided into control group and treatment group according to random number table method, with 50 cases in each group. Patients in the control group were po administered with Amitriptyline Hydrochloride Tablets, 25 mg/time, three times daily. Patients in the treatment group were po administered with Oxazepam Tablets on the basis of the control group, 30 mg/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy and symptom improvement time of the two groups were observed. The changes of Hamilton Depression Scale (HAMD) score, SCL-90 score, interleukin 6 (IL-6), interleukin 2 (IL-2), tumor necrosis factor (TNF-α) and interleukin 1β (IL-1β) levels were compared between the two groups before and after treatment.Results After treatment, the total effective rate of treatment group was 98.0%, significantly higher than that of control group 80.0% (P < 0.05). After treatment, the improvement time of symptoms such as difficulty falling asleep, decreased appetite, fatigue and weakness, and emotional irritability in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, HAMD score and SCL-90 score in two groups were significantly decreased compared with before treatment (P < 0.05). After treatment, HAMD score and SCL-90 score were lower than those of control group (P < 0.05). After treatment, the levels of IL-6, IL-2, TNF-α and IL-1β in two groups were significantly decreased compared with before treatment (P < 0.05). The level of serological indexes in treatment group was lower than that in control group (P < 0.05).Conclusion Oxazepam combined with amitriptyline has definite effect in treatment of depression, and can obviously improve symptoms, reduce inflammatory cytokines, which is worthy of clinical promotion.

R971

蕪湖市科技計(jì)劃項(xiàng)目(2019cg20)